血栓炎症在缺血性中风中的作用:关注操纵和临床应用
Yuanfei Luo1, Weichen Dong1, Linying Yuan1
1Department of Neurology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Molecular neurobiology
|August 6, 2024
概括
缺血性中风治疗可能会导致由于血栓炎症引起的再流伤害. 针对这种涉及血小板和炎症的过程,可能为中风恢复提供新的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 心血管医学 心血管医学
背景情况:
- 脑卒中对经济和健康造成重大负担,患病率和死亡率很高.
- 缺血-再输液 (I/R) 损伤是中风重血管化后的常见并发症,结果恶化.
- 血栓炎症是中风病理生理学的关键过程,涉及血小板激活,内皮损伤和炎症细胞透.
研究的目的:
- 审查血栓炎症在缺血性中风中的机制.
- 讨论针对血栓炎症的最新研究进展.
- 通过调节血栓炎症来评估治疗I/R损伤的治疗策略的临床可行性.
主要方法:
- 在缺血性中风和I / R损伤中对血栓炎症的研究的文献综述.
- 对治疗干预的临床前和临床数据的分析.
- 综合有关药物机制和临床潜力的信息.
主要成果:
- 血栓炎症显著导致I / R损伤,其特点是血小板激活和炎症反应.
- 目前的治疗方法侧重于抑制血小板和中性粒细胞的激活.
- 现有的药物,如抗血小板,抗凝固剂和葡萄皮质类药物显示出潜力,与新药一起.
- 大多数有前途的疗法仍处于临床前阶段.
结论:
- 血栓炎症是减轻中风后缺血-再输液损伤的关键治疗标.
- 需要进一步的研究和临床试验,以将临床前发现转化为有效的治疗方法.
- 调节血栓炎症有望改善中风患者的治疗结果.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
657
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
657
01:16Clot Retraction and Fibrinolysis
5.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.1K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
502
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
502
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
6.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.7K
01:22Formation of the Platelet Plug
5.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
5.5K